SCHEDULE 2 – THE SERVICES

A. Service Specifications

Service Specification No.	11J/0258		
Service	Cancer Prevention and Earlier Diagnosis Local Enhanced		
	Service		
Commissioner Lead	Dorset Cancer Partnership & Wessex Cancer Alliance		
Provider Lead	Dorset Primary Care Networks		
Period	01 January 2021 – 31 December 2022		
Date of Review	April 2022		

1. Population Needs

1.1 National/local context and evidence base

Dorset Cancer Partnership

 The Dorset Cancer Partnership has delegated authority from the Dorset Integrated Care System for the delivery and assurance of cancer services and cancer standards, and to deliver transformation to achieve the cancer elements of the NHS Long Term Plan. The DCP is a member of the Wessex Cancer Alliance.

Wessex Cancer Alliance

 Wessex Cancer Alliance is responsible for overseeing the delivery of cancer care across Wessex, by supporting the Integrated Care Systems in Dorset, Hampshire and the IOW. The Alliance will ensure Wessex meets the requirements and goals for cancer diagnosis, care, treatment and outcomes that are established in the NHS Long Term Plan, published in January 2019.

Cancer Prevention and Earlier Diagnosis LES

 This Cancer Early Prevention and Earlier Diagnosis LES is a central part of the Dorset Cancer Partnership and Wessex Cancer Alliance plans to support PCNs to achieve the Early Cancer Diagnosis DES and QoF QI. For background information see Appendix C.

2. Outcomes

2.1 NHS Outcomes Framework Domains & Indicators

Domain 1	Preventing people from dying prematurely	✓
Domain 2	Enhancing quality of life for people with long-term conditions	✓
Domain 3	Helping people to recover from episodes of ill-health or following injury	
Domain 4	Ensuring people have a positive experience of care	✓
Domain 5	Treating and caring for people in safe environment and protecting them from avoidable harm	✓

2.2 Local defined outcomes

- Increase understanding of prevention, screening and signs and symptoms of cancer in the patient population.
- Improving referral practice through the use of Clinical Decision Support Tools; Increasing uptake of Faecal Immunochemical Testing.

3. Scope

3.1 Aims and objectives of service

This LES is a supplement to the Early Cancer Diagnosis PCN DES. Our aim is to support PCNs by offering the considerable expertise in the Cancer Alliance and Dorset Cancer Partnership and useful resources for use in general practice in the Prevention and Earlier Diagnosis Toolkit.

This service specification builds on the outputs from the Early Detection of Cancer LES in Dorset in 2020/21 (learning from this has been used to develop this agreement – see Appendix B).

3.2 Service description/care pathway

Requirement	Details	WCA/DCP support
Continue to have clinical and non-clinical cancer champion.	 To be the nominated points of contact To complete the initial reporting in Appendix A To join 2 webinars (or an appropriate deputy if not available) and cascade information to the PCN. 	 November 2021 - Introductory webinar covering the current priorities, the Prevention and Earlier Diagnosis Toolkit and key members of the team. May 2022 – Mid-point webinar to report on progress and address any barriers

Requirement	Details	WCA/DCP support
Non Clinical cancer champion to guide their PCN to complete the following non- clinical elements	 Receive and distribute WCA primary care newsletter and other communications to ensure PCN members are aware of contents. Work with your clinical champion to use a variety of 	 See accompanying Prevention and Earlier Diagnosis Toolkit primarycaretoolkit Access to the DCP Non-clinical cancer champion network which will be supported by CRUK facilitators.

methods appropriate to your PCN population to oprovide messaging to encourage patients to spot the signs and symptoms of cancers and to present to the GP earlier; oprovide cancer prevention messaging to stop smoking, reduce alcohol intake, improve diet and increase exercise.

Requirement	Details	WCA/DCP support
Clinical cancer champion guide their PCN to complete the following clinical elements		
1. Review the use of symptomatic Faecal Immunochemical Test (FIT) in the PCN.	 Join or access recording of the 1 hr webinar about colorectal cancer and the use of symptomatic FIT or complete Gateway C e-learning module on FIT https://www.gatewayc.org.uk/courses/ Identify areas for improvement Share learning and plans for improvement with DCP 	1 hr webinar about colorectal cancer and the use of symptomatic FIT Resources in the Prevention and Earlier Diagnosis Toolkit primarycaretoolki
2. Increase the use of clinical decision support tools for the diagnosis of cancer and safety netting.	 Join webinar showcasing clinical decision support tools. Trial a CDS tool in your PCN Complete short 'before and after' survey to enable monitoring of change Submit your reflections within the safety netting survey 	 1 hr webinar showcasing free and easy to use tools that enhance referral and recognition and safety-netting. Additional information and support in the Prevention and Earlier Diagnosis

	•	Toolkit primarycaretoolkit DCP to provide survey	

3.3 Population Covered

Dorset population registered with a Dorset GP surgery

3.4 Any acceptance and exclusion criteria.

n/a

3.5 Interdependence with other services/providers

Following on from 2020/21 Local Enhanced Service

4. Applicable Service Standards

4.1 Applicable national standards (eg NICE)

The NHS Long Term Plan

https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/

Investment and evolution: A five-year framework for GP contract reform to implement The NHS Long Term Plan

<u>Https://www.bma.org.uk/collective-voice/committees/general-practitioners-committee/gpc-england/gpcontract-agreement-england</u>

4.2 Applicable standards set out in Guidance and/or issued by a competent body (eg Royal Colleges)

n/a

4.3 Applicable local standards

- The CCG reserves the right to undertake post payment verification of any aspect of the Improvement Plan.
- PCNs should be aware that, if they receive a payment under this Improvement
 Plan but cannot demonstrate that they are participating fully in all aspects of it,
 the CCG reserves the right to withhold and/or require return of payments.
 Before taking such action, the CCG will give appropriate notice and seek to agree
 an action plan with the PCN concerned to address the CCG's concerns.

5. Applicable quality requirements and CQUIN goals

5.1 Applicable quality requirements (See Schedule 4A-C) General

n/a

5.2 Applicable CQUIN goals (See Schedule 3E)

n/a

Location of Provider Premises

The Provider's Premises are located at:

Dorset Primary Care Networks

7. Individual Service User Placement

n/a

8. Applicable Personalised Care Requirements

8.1 Applicable requirements, by reference to Schedule 2M where appropriate

n/a

Appendix A

Initial reporting

Contact details for Cancer Champions		
PCN name		
Name of Non Clinical Cancer Champion		
Role		
Email address		
Name of Clinical Cancer Champion		
Role		
Email address		
Which ARRS roles does your PCN employ/intend to employ?		

Please return this information to DCP@dorsetccg.nhs.uk this will signify your willingness to join the local enhanced service.

Appendix B


Learning from Dorset Cancer Partnership LES 2019/20

Early Detection of Cancer LES


- 1.1. The Early Detection of Cancer LES was agreed for delivery by 17 of 18 PCNs in Dorset, which started in October 2020 and was planned to end in March 2021. Many PCNs started delivery in Quarter 4 of 2020/21 due to the pandemic and so the reporting deadline was extended to end of April 2021. 15 PCNs have returned reports which is very positive considering the pressures in primary care. The reports are very detailed covering the audit findings and the themes identified. PCN improvement plans have also been developed and submitted which reflect the findings from the audit work. See Appendix 1 for the service specification.
- 1.2. Several PCNs identified males as more likely to be diagnosed at a late stage and one PCN observed patients with late stage cancer were mostly overweight or obese. Training of long term condition nurses was identified as an action for this PCN to reach some of this cohort. There were repeated themes around particular tumour sites where patients had a delayed diagnosis due to a routine rather than 2ww referral; this was common for lung and lower GI; and less commonly reported but important for ovarian and pancreatic where symptoms were less specific. Prostate cancer was often diagnosed at late stage and PCNs have found this difficult to address, with some suggestions of increased PSA testing, and acknowledgement of the challenges of diagnosing prostate cancers that progress very slowly.
- 1.3. Some PCNs have put in place processes for ensuring patients are offered urgent blood tests at the time of a 2ww referral and to ensure all 2ww referred patients are given information about their referral.

1.4. The three main themes that came from the analysis of the PCN audits were:

- 1) the need for clinical referrers to be aware of NICE guidance NG12 for suspected cancer referrals;
- 2) the need for safety netting of patients;
- 3) the need for the public to have more understanding of cancer symptoms and to present to their GP if concerned.
- 1.5. Themes 1 and 3 are within the draft LES deliverables for 2021/22 together with a package of support from the DCP and WCA. Theme 2 will be supported by the Cancer Research UK facilitators, one of whom is now working within the DCP, and will offer support to PCNs to put in place or improve safety netting procedures.
- 1.6. One of the requirements of this LES was completion by all clinical referrers of the Gateway C online cancer training module 'Improving the quality of your referral' (IQR). Dorset CCG now has the highest Gateway C registration and course completion rates in England (bar Greater Manchester, see below) driven by this LES and we are sharing how we achieved this with other CCGs and Alliances. In June we had 600 users in Dorset covering 95% of our GP practices (charts below Gateway C registered users up to June 2021; Greater Manchester excluded from charts because they were part of creating Gateway C and began using it earlier; for context, Dorset is around 30% of the Wessex population).



CCG breakdown




- 1.7. 244 Dorset based clinical referrers (mainly GPs plus some ANPs) have completed the IQR module to date. The course covers the following:
 - Clinical decision making
 - Helping to reduce DNAs
 - Key information to include in a referral
 - Safety netting
 - · What patients want to know
 - The Cancer Maps
- 1.8. The Cancer Maps are a type of Clinical Decision Support (CDS) Tool, of which there is a requirement in the national DES for these tools to be implemented. A recent survey from WCA to PCNs across Wessex to identify which CDS tools were in use found that GPs in Dorset frequently cited use of Cancer Maps, which was not reflected across Hants and Isle of Wight, and this is likely to be as a result of the LES in 2020/21; we have had feedback from GPs as part of the LES reports that the Cancer Maps are very useful.
- 1.9. Another requirement was for PCNs to nominate a clinical and non-clinical cancer champion; we have now created a network for these cancer champions with a central Teams site for communicating and sharing information. The PCN conference in April 2021 brought these champions together for the first time. We will continue to build on this network over the next four years aligned with the national DES and the Cancer Prevention and Early Detection Programme plan for Dorset.

Background information







×

Age-standardised 1-year net survival (%) for adults diagnosed in the period 2012 to 2016 and followed up to 2017: 14 common cancers, by sex for selected Cancer Alliances

Wessex

■ Female ■ Male ■ Female 60 Prostate Breast Uterus Cervix Rectal Myeloma Kidney & Urinary Tract Non-Hodgkin Lymphoma Colorectal Bladder

survival in England has been increasing over time and is the highest it has ever been, as the chart below shows.

One year survival rates vary enormously between different cancers with lung cancer survival rates at 36% for men and 44% for women in Wessex, and prostate cancer survival rates at 96% and breast cancer rates at 95% in Wessex. See chart below

NICE Suspected Cancer Guidance 2015 However to make further improvements in cancer survival requires a significant focus on

Colon

Stomach

Oesophagus

35 40 45 50 55 60 65 70 75 80 85 90 95 1-year survival estimate (%)

achieving earlier staging at diagnosis. In 2015, NICE published guidance for Suspected Cancer: Recognition and Referral (NG12₁) setting out the guidance for 2ww referral, and more importantly lowering the threshold of suspicion to 3% in order to identify cancer at an earlier stage₂.

NHS Long Term Plan 2019

Following on from this in 2019, the NHS Long Term Plan was published and included an ambition that 75% of cancers should be diagnosed at stage 1 & 2 by 2028. Achieving this will mean that, from 2028, 55,000 more people in England each year will survive their cancer for at least five years after diagnosis. The NHS Long Term Plan says we will build on work to raise greater awareness of symptoms of cancer, lower the threshold for referral by GPs, accelerate access to diagnosis and treatment and maximise the number of cancers that we identify through screening. This includes the use of personalised and risk stratified screening and beginning to test the family members of cancer patients where they are at increased risk of cancer.

The Early Cancer Diagnosis DES includes the following areas of focus:

- Review 2ww referral practice and quality (e.g. use of clinical decision support tools, review of patterns of presentations and diagnoses of cancer, use of new rapid diagnostic pathway);
- Ensure a consistent response to safety netting patients referred via a 2ww or for further investigations to exclude the possibility of cancer;
- Ensure patients receive information about their 2ww referral;
- Contribute to improving uptake of national cancer screening programmes;
- Support delivery of the above through a community of practice, including peer learning events and engagement with local system partners.

The Quality Outcomes Framework (QOF) has been developed to support the roll out of the PCN early cancer diagnosis service specification in 2020/21. The full module can be read here: https://www.england.nhs.uk/gp/investment/gp-contract/.

The two QOF indicators are:

- QIECD005 The contractor can demonstrate continuous quality improvement activity focused upon early cancer diagnosis as specified in the QOF guidance.
- QIECD006 The contractor has participated in network activity to regularly share and discuss learning from quality improvement activity focused on early cancer diagnosis as specified in the QOF guidance. This would usually include participating in a minimum of two peer review meetings.